Oral Involvement

  • Crispian Scully
  • Eleni A. Georgakopoulou


This chapter summarizes the orofacial involvement in Sjögren syndrome (SS). Oral manifestations of SS are mainly xerostomia and hyposalivation, autoimmune sialadenitis causing salivary gland swelling, and secondary manifestations such as dental caries, oral candidiasis, bacterial sialadenitis, oral malodour, and oral ulcers. These secondary manifestations are the first features of the disease to become ­evident in approximately half of the patients with primary SS, and their identification is important for early diagnosis. Furthermore, as most SS patients consider oral complications a major factor of quality of life deterioration [1], their treatment should be a priority.


Salivary Gland Dental Caries Salivary Flow Rate Denture Stomatitis Angular Cheilitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fox PC, Bowman SJ, Segal B, Vivino FB, Murukutla N, Choueiri K, et al. Oral involvement in primary Sjögren syndrome. J Am Dent Assoc. 2008;139:1592–601.PubMedGoogle Scholar
  2. 2.
    Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res. 2000;79:1874M.CrossRefGoogle Scholar
  3. 3.
    Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res. 1992;71:1363.PubMedCrossRefGoogle Scholar
  4. 4.
    Kohler PF, Winter ME. A quantitative test for xerostomia. The saxon test, an oral equivalent of the schirmer test. Arthritis Rheum. 2005;28:1128–32.CrossRefGoogle Scholar
  5. 5.
    Jorkjend L, Johansson A, Johansson AK, Bergenholtz A. Resting and stimulated whole salivary flow rates in Sjögren’s syndrome patients over time: a diagnostic aid for subsidized dental care? Acta Odontol Scand. 2004;62(5):264–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Moore PA, Guggenheimer J. Medication-induced hyposalivation: etiology, diagnosis, and treatment. Compend Contin Educ Dent. 2008;29(1):50–5.PubMedGoogle Scholar
  7. 7.
    Turner MD, Ship JA. Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc. 2007;138(Suppl):15S–20.PubMedGoogle Scholar
  8. 8.
    Thomson WM, Lawrence HP, Broadbent JM, Poulton R. The impact of xerostomia on oral-health-related quality of life among younger adults. Health Qual Life Outcomes. 2006;4:86.PubMedCrossRefGoogle Scholar
  9. 9.
    Johansson AK, Johansson A, Unell L, Ekbäck G, Ordell S, Carlsson GE. A 15-yr longitudinal study of xerostomia in a Swedish population of 50-yr-old subjects. Eur J Oral Sci. 2009;117(1):13–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Meurman JH, Tarkkila L, Tiitinen A. The menopause and oral health. Maturitas. 2009;63(1):56–62. Epub 2009 Mar 25.PubMedCrossRefGoogle Scholar
  11. 11.
    Baum BJ, Ship JA, Wu AJ. Salivary gland function and aging: a model for studying the interaction of aging and systemic disease. Crit Rev Oral Biol Med. 1992;4(1):53–64.PubMedGoogle Scholar
  12. 12.
    Yamamoto K, Nagashima H, Yamachika S, Hoshiba D, Yamaguchi K, Yamada H, et al. The application of a night guard for sleep-related xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(3):e11–4. Epub 2008 Jul 7.PubMedCrossRefGoogle Scholar
  13. 13.
    Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004;164(12):1275–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Cho MA, Ko JY, Kim YK, Kho HS. Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology. J Oral Rehabil. 2010;37(3):185–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Longman LP, Higham SM, Bucknall R, Kaye SB, Edgar WM, Field EA. Signs and symptoms in patients with salivary gland hypofunction. Postgrad Med J. 1997;73(856):93–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Flaitz CM. Parotitis as the initial sign of juvenile Sjögren’s syndrome. Pediatr Dent. 2001;23(2):140–2.PubMedGoogle Scholar
  17. 17.
    Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Wolff A. Sjögren’s syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation/xerostomia. J Oral Pathol Med. 2005;34(1):1–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Mellgren SI, Göransson LG, Omdal R. Primary Sjögren’s syndrome associated neuropathy. Can J Neurol Sci. 2007;34(3):280–7.PubMedGoogle Scholar
  19. 19.
    Haldorsen K, Moen K, Jacobsen H, Jonsson R, Brun JG. Exocrine function in primary Sjögren syndrome: natural course and prognostic factors. Ann Rheum Dis. 2008;67(7):949–54. Epub Oct 25, 2007.PubMedCrossRefGoogle Scholar
  20. 20.
    Alliende C, Kwon YJ, Brito M, Molina C, Aguilera S, Pérez P, et al. Reduced sulfation of muc5b is linked to xerostomia in patients with Sjögren syndrome. Ann Rheum Dis. 2008;67(10):1480–7. Epub 2007 Nov 12.PubMedCrossRefGoogle Scholar
  21. 21.
    Reina S, Orman B, Anaya JM, Sterin-Borda L, Borda E. Cholinoreceptor autoantibodies in Sjögren syndrome. J Dent Res. 2007;86(9):832–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Mathews SA, Kurien BT, Scofield RH. Oral manifestations of Sjögren’s syndrome. J Dent Res. 2008;87(4):308–18.PubMedCrossRefGoogle Scholar
  23. 23.
    Helenius LM, Meurman JH, Helenius I, Kari K, Hietanen J, Suuronen R, et al. Oral and salivary parameters in patients with rheumatic diseases. Acta Odontol Scand. 2005;63(5):284–93.PubMedCrossRefGoogle Scholar
  24. 24.
    Hjelmervik TO, Jonsson R, Bolstad AI. The minor salivary gland proteome in Sjögren’s syndrome. Oral Dis. 2009;15(5):342–53. Epub Apr 2, 2009.PubMedCrossRefGoogle Scholar
  25. 25.
    Silvestre FJ, Puente A, Bagán JV, Castell JV. Presence of fibronectin peptides in saliva of patients with Sjögren’s syndrome: a potential indicator of salivary gland destruction. Med Oral Patol Oral Cir Bucal. 2009;14(8):e365–70.PubMedGoogle Scholar
  26. 26.
    Navazesh M. How can oral health care providers determine if patients have dry mouth? J Am Dent Assoc. 2003;134(5):613–8.PubMedGoogle Scholar
  27. 27.
    Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009;48(9):1077–82. Epub Jun 24, 2009.CrossRefGoogle Scholar
  28. 28.
    Stewart CM, Berg KM, Cha S, Reeves WH. Salivary dysfunction and quality of life in Sjögren syndrome: a critical oral-systemic connection. J Am Dent Assoc. 2008;139(3):291–9; quiz 358–9.PubMedGoogle Scholar
  29. 29.
    Guobis Z, Baseviciene N, Paipaliene P, Niedzelskiene I, Januseviciūte G. Aspects of xerostomia prevalence and treatment among rheumatic inpatients. Medicina (Kaunas). 2008;44(12):960–8.Google Scholar
  30. 30.
    Seo DG, Kim J, Lee CY, Park SH. Diagnosis of Sjögren’s syndrome from a xerostomia case accompanied by multiple dental caries. Oper Dent. 2009;34(3):359–64.PubMedCrossRefGoogle Scholar
  31. 31.
    Llena C, Forner L, Baca P. Anticariogenicity of casein phosphopeptide-amorphous calcium phosphate: a review of the literature. J Contemp Dent Pract. 2009;10(3):1–9.PubMedGoogle Scholar
  32. 32.
    Singh ML, Papas AS. Long-term clinical observation of dental caries in salivary hypofunction patients using a supersaturated calcium-phosphate remineralizing rinse. J Clin Dent. 2009;20(3):87–92.PubMedGoogle Scholar
  33. 33.
    Scardina GA, Ruggieri A, Messina P. Periodontal disease and Sjögren syndrome: a possible correlation? Angiology. 2010;61(3):289–93.PubMedCrossRefGoogle Scholar
  34. 34.
    Mutlu S, Porter SR, Richards A, Scully C, Maddison P. Gingival and periodontal health in Sjogren’s syndrome and other connective tissue disorders. Clin Exp Rheumatol. 1993;11:95–6.PubMedGoogle Scholar
  35. 35.
    Antoniazzi RP, Miranda LA, Zanatta FB, Islabão AG, Gustafsson A, Chiapinotto GA, et al. Periodontal conditions of individuals with Sjögren’s syndrome. J Periodontol. 2009;80(3):429–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Boutsi EA, Paikos S, Dafni UG, Moutsopoulos HM, Skopouli FN. Dental and periodontal status of Sjögren’s syndrome. J Clin Periodontol. 2000;27:231–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Schiødt M, Christensen LB, Petersen PE, Thorn JJ. Periodontal disease in primary Sjögren’s syndrome. Oral Dis. 2001;7(2):106–8.PubMedGoogle Scholar
  38. 38.
    Gomes SG, Custódio W, Cury AA, Garcia RC. Effect of salivary flow rate on masticatory efficiency. Int J Prosthodont. 2009;22(2):168–72.PubMedGoogle Scholar
  39. 39.
    Turner M, Jahangiri L, Ship JA. Hyposalivation, xerostomia and the complete denture: a systematic review. J Am Dent Assoc. 2008;139(2):146–50.PubMedGoogle Scholar
  40. 40.
    Leung KC, McMillan AS, Cheung BP, Leung WK. Sjögren’s syndrome sufferers have increased oral yeast levels despite regular dental care. Oral Dis. 2008;14(2):163–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Radfar L, Shea Y, Fischer SH, Sankar V, Leakan RA, Baum BJ, et al. Fungal load and candidiasis in Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96(3):283–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002;78:455–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Scully C, El-Kabir M, Samaranayake LP. Candida and oral candidosis. Crit Rev Oral Biol Med. 1994;5:124–58.Google Scholar
  44. 44.
    Torres SR, Peixoto CB, Caldas DM, Akiti T, Barreiros MG, de Uzeda M, et al. A prospective randomized trial to reduce oral Candida spp. colonization in patients with hyposalivation. Braz Oral Res. 2007;21(2):182–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Nagy K, Urban E, et al. Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. J Craniofac Surg. 2007;18:1157.PubMedCrossRefGoogle Scholar
  46. 46.
    Lundström IM, Lindström FD. Subjective and clinical oral symptoms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 1995;13(6):725–31.PubMedGoogle Scholar
  47. 47.
    Bartunková J, Sedivá A, Vencovsky J, Tesar V. Primary Sjögren’s syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17:381–6.PubMedGoogle Scholar
  48. 48.
    Khosroshahi A, Stone JH. IgG4-related systemic disease: overview of the clinical features. Curr Opin Rheumatol. 2011;23:57–66.PubMedCrossRefGoogle Scholar
  49. 49.
    Yamamoto M, Harada S, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. Clinical and pathological differences between Mikulicz’s disease and Sjogren’s syndrome. Rheumatology. 2005;44:227–34.PubMedCrossRefGoogle Scholar
  50. 50.
    Yamamoto M, Harada S, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease. Mod Rheumatol. 2006;16:335–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Manoussakis MN. Sjogren’s Syndrome Orphanet encyclopedia. November 2001
  52. 52.
    Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Roh LJ, Huh J, Suh C. Primary non-Hodgkin’s lymphomas of the major salivary glands. J Surg Oncol. 2008;97:35–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, The Members of the European Concerted Action on Sjögren’s Syndrome. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren’s syndrome. Arthritis Rheum. 1999;42:1765–72.PubMedCrossRefGoogle Scholar
  55. 55.
    Smedby KE et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–38.CrossRefGoogle Scholar

Key Websites (Accessed Dec 19, 2009)

  1. Miller AV, Ranatunga SKM, Francis ML. Sjögren syndrome: differential diagnoses & workup.
  2. Miller AV, Ranatunga SKM, Francis ML. Sjögren syndrome: treatment & medication.

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Crispian Scully
    • 1
  • Eleni A. Georgakopoulou
    • 2
  1. 1.Division of Maxillofacial Diagnostic, Medical and Surgical SciencesUniversity College London (UCL) – Eastman Dental InstituteLondonUK
  2. 2.First Department of Dermatology and Venereology, A. Syggros Hospital, School of MedicineUniversity of AthensAthensGreece

Personalised recommendations